Observational studyScientific reports2026
Inflammatory molecules in tear fluid in retinitis pigmentosa: an exploratory case-control study.
Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This observational case-control study aimed to compare tear-fluid inflammatory mediator profiles between patients with retinitis pigmentosa (RP) and healthy controls (HC), and to explore associations with RP severity, anxiety, daytime sleepiness, and sleep quality. A total of 78 adults with confirmed RP and 32 HC from a reference controlled-environment cohort were enrolled. RP participants completed anxiety, sleep quality, and sleepiness questionnaires. Tear samples were collected under standardized controlled-environment conditions, and biomarker analyses were conducted using one tear sample per participant. A customized multiplex panel was quantified using xMAP/Luminex technology, and substance P (SP) was measured by competitive ELISA. Between-group differences and within-RP associations were initially assessed using multivariable models adjusted for age and sex, with multiplicity controlled using the Benjamini-Hochberg false discovery rate (BH-FDR) in exploratory analyses. Given the age/sex imbalance between groups, additional sensitivity analyses were performed, including restriction to the overlapping age range, sex-stratified analyses, and inverse probability weighting based on age and sex and 1:1 age- and sex- ased matching. RP tear fluid showed a consistent pattern of lower mediator concentrations and reduced detectability compared with controls. In the main quantitative analyses, RP participants had significantly lower levels of EGF, GRO, IL-8, MCP-1, and IL-1RA, and these between-group patterns were directionally consistent across sensitivity analytes. For low-detection analytes, RP participants also showed reduced detectability relative to controls, although these results should be interpreted more cautiously. Within the RP cohort, tear biomarker profiles were broadly similar across clinical severity and anxiety, sleep quality, and sleepiness strata, with no associations remaining significant after BH-FDR correction. These findings suggest that tear-fluid immune mediators may provide complementary, non-invasive information on ocular surface neuroimmune alterations in RP; however, because the control cohort was not prospectively age- and sex-matched and tear-dilution normalization variables were not available, the between-group findings should be interpreted as exploratory and hypothesis-generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.